Found 373 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Hydrocephalus is a medical condition in which an abnormal buildup of cerebrospinal fluid (CSF) causes the fluid-filled spaces of the brain, the ventricles, to become enlarged. Enlarged ventricles and increased intracranial pressure can cause headaches, dizziness, blurred vision, cognitive impairment, gait disturbances and in severe cases even brain herniation or …
The OPTIMIZER Smart Post-Approval Study (PAS) is a single arm open label study of 620 participants receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%.
Create a biorepository and database to support future research on cryptogenic NORSE. Laboratory and pathological assessments of blood and tissue will include proteomic analysis, genetic profiling, exome sequencing and microbiome analysis. Subjects are expected to be recruited using a LAR. Biorepository located at Yale.
Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or …
The aim is to prospectively evaluate the efficacy and mechanism of benefit of HI-CRT vs. BIV CRT in patients with Right Bundle Brank Block (RBBB). Left Ventricular Ejection Fraction (LVEF) will be assess at 6 months following HIS CRT Vs. BIV CRT implant in Heart Failure patients with RBBB.
This is a substudy of an umbrella study (MK-3475-U1). Subjects will be enrolled to the screening protocol and then subsequently enrolled to one of the substudies. This substudy examines investigational agents (MK-7684, MK-5890, MK-4830) in combination with pembrolizumab plus standard chemotherapy in treatment-naïve participants with advanced NSCLC.
Among lung transplant recipients who survive to 5 years, half suffer from chronic lung allograft dysfunction (CLAD). This study will evaluate how changes in the lung microbiome may cause CLAD in Cystic Fibrosis patients who have been transplanted. This is a case-control study of Cystic Fibrosis lung transplant recipients to …
The goal of this project is to test a novel approach to initiating buprenorphine treatment for OUD that can be used in outpatient setting without requiring or precipitating opioid withdrawal. Subjects will be randomized to one of two arms: standard initiation, in which subjects will start buprenorphine after 8 hours …
The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of …
Subjects with unusual lipids in subjects with known or suspected genetic variants that may be associated with change in lipoprotein kinetics will have two-night, one-day inpatient stay in CHPS, during which they will undergo extensive evaluation of lipoprotein kinetics using stable isotope techniques, OFTT, and OGTT. Subjects will complete a …
